ACTU
Actuate Therapeutics Inc
NASDAQ · Healthcare · Biotechnology · US
$1.48
+8.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 8.9M | 10.3M | 18.7M | 21.7M | 16.4M |
| SG&A Expense | 11.8M | 12.2M | 6.5M | 3.3M | 3.8M |
| General & Admin Expense | 9.3M | 12.2M | 6.5M | 3.3M | 3.8M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 20.8M | 22.5M | 25.2M | 25.0M | 20.2M |
| Cost and Expenses | 20.8M | 22.5M | 25.2M | 25.0M | 20.2M |
| Operating Income (EBIT) | (20.8M) | (22.5M) | (25.2M) | (25.0M) | (20.2M) |
| Non-Operating | |||||
| Interest Income | 339.8K | 287.7K | 222.3K | 352.7K | 27.0K |
| Interest Expense | 20.3K | 20.3K | (18.7K) | 43.6K | 16.2K |
| Net Interest Income | 319.6K | 267.5K | 241.0K | 309.0K | 10.8K |
| Other Non-Op Income/Expense | 319.6K | 267.5K | (2.1M) | 229.2K | 47.4K |
| Non-Operating Income (excl Interest) | (294.8K) | (287.7K) | 2.1M | (272.9K) | (63.6K) |
| EBT (Pre-Tax Income) | (20.5M) | (22.2M) | (27.3M) | (24.7M) | (20.2M) |
| Income Tax Expense | 800.00 | — | 800.00 | — | — |
| Bottom Line | |||||
| Net Income | (20.5M) | (22.2M) | (27.3M) | (24.7M) | (20.2M) |
| Earnings from Cont. Ops | (20.5M) | (22.2M) | (27.3M) | (24.7M) | (20.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (20.5M) | (22.2M) | (27.3M) | (24.7M) | (20.2M) |
| Per Share | |||||
| Basic EPS | ($0.89) | ($1.06) | ($3.26) | ($1.65) | ($1.34) |
| Diluted EPS | ($0.89) | ($1.06) | ($3.26) | ($1.65) | ($1.34) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 23.9M | 21.0M | 19.5M | 15.0M | 15.0M |
| Diluted Shares Outstanding | 23.9M | 21.0M | 19.5M | 15.0M | 15.0M |
| Profitability Metrics | |||||
| EBITDA | (20.5M) | (22.2M) | (25.2M) | (24.4M) | (20.1M) |
| D&A | — | — | 2.1M | 272.9K | 63.6K |
| EBIT | (20.5M) | (22.2M) | (27.3M) | (24.7M) | (20.1M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026